Author | Aleix Prat, MD, PhD | OncLive

Author | Aleix Prat, MD, PhD


Dr. Prat on HER2-Enriched Subtype as Strong Predictor of HER2-Targeted Treatment

December 15, 2016


Aleix Prat, MD, PhD, head of the Department of Medical Oncology, the August Pi i Sunyer Biomedical Research Institute, discusses the results of the open-label PAMELA trial, in which the HER2-enriched subtype predicted pathologic complete response to targeted treatment in patients with HER2-positive, hormone receptor-positive breast cancer.

Dr. Prat on the Differences Between EndoPredict and Prosigna

June 09, 2014


Aleix Prat, MD, PhD, medical oncologist, Vall D'Hebron Institute of Oncology, Barcelona, Spain, discusses the differences between EndoPredict and Prosigna.